NPC 567

Drug Profile

NPC 567

Alternative Names: NOVA 567

Latest Information Update: 18 Aug 1995

Price : $50

At a glance

  • Originator Scios
  • Developer GlaxoSmithKline; Scios
  • Class Antiasthmatics; Kinins; Neuropeptides; Oligopeptides
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 18 Aug 1995 Discontinued-II for Burns in USA (Topical)
  • 18 Aug 1995 Discontinued-II for Burns in United Kingdom (Topical)
  • 18 Aug 1995 Discontinued-II for Asthma in United Kingdom (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top